T he standard treatment of stage I non-small cell lung cancer (NSCLC) is lobectomy with systematic mediastinal lymph node evaluation.
Respiratory failure and pulmonary complications represent the most signifi cant risks following lung resection, and preprocedural risk assessment is based primarily on pulmonary function. Currently available treatment techniques for high-risk patients with stage I NSCLC include sublobar resection with or without brachytherapy, stereotactic body radiotherapy (SBRT), and radiofrequency ablation (RFA). Each of these modalities has historically been associated with decreased procedural morbidity and mortality but increased involved lobe and regional recurrence when compared with lobectomy. Improvements in radiographic staging and the detection of smaller and more indolent tumors push risk/benefi t decisions toward parenchymal sparing or nonoperative therapies in this population. Unbiased assessment of treatment options for high-risk patients requires uniform reporting of comorbidities and outcomes in clinical series, which has been lacking to date. 
Medical Assessment

Relevant Outcome Measures
Health-related functional status and qualityof-life assessment are important and underreported for the treatment of high-risk patients with stage I NSCLC and suggested for inclusion in clinical decisions.
Sublobar Resection
5.
Segmentectomy or extended wedge resection with margins . 1 cm or equal to the tumor diameter with hilar and mediastinal nodal evaluation is suggested as a safe and effective alternative to lobectomy in highrisk patients with stage I NSCLC. 6. In patients with stage I NSCLC . 75 years of age, segmentectomy or extended wedge resection is suggested as an effective and potentially benefi cial alternative to lobectomy. 7. Anatomic segmentectomy is preferred when possible to wedge resection in patients who undergo sublobar resection for stage I NSCLC.
Adjuvant intraoperative brachytherapy
should be considered in conjunction with sublobar resection to reduce involved lobe recurrence.
Radiation Therapy
Conventionally fractionated radiation therapy with definitive intent and sufficient dose intensity is a reasonable treatment
Introduction
Recommended treatment of stage I non-small cell lung cancer (NSCLC) is complete resection of the primary tumor by lobectomy and associated lymphatics. Operative mortality rates for lobectomy are currently 1% to 5%, 1 -3 but patients with underlying lung disease have inherent increased risk. Although no single test can determine the safety of resection, much is known about the relative risks. Numerous variables have been examined as predictors of morbidity and mortality after lung resection, but controversy continues. What constitutes prohibitive risk in a lethal disease such as NSCLC remains a matter of judgment, and clinicians must weigh risks, benefi ts, and patients' preferences when making treatment recommendations.
Lobectomy with systematic mediastinal node evaluation has been the accepted standard treatment of early-stage NSCLC since the 1940s. The morbidity and mortality of lobectomy has changed over time and will likely continue to decrease with evolving techniques. Sublobar resection has been performed for patients with stage I NSCLC with poor pulmonary reserve for many decades, and nonsurgical treatment options have recently arisen, including stereotactic body radiotherapy (SBRT) and percutaneous ablative therapy (radiofrequency ablation [RFA] , cryoablation, and microwave ablation). These treatments appear to decrease the risk of respiratory failure, disability, and death, but have limited evidence of effi cacy compared with lobectomy .
Up to 25% of patients with clinical stage I NSCLC have limited pulmonary reserve, 4 representing nearly 10,000 individuals each year in the United States. Patients with untreated stage I NSCLC have a median survival of only 18 months. 5 Despite high competitive mortality from severe underlying lung disease, the mortality related to untreated NSCLC cannot be ignored in most patients. This project is an expert consensus opinion with regard to the evaluation and treatment of high-risk patients with stage I NSCLC to assist clinicians in tailoring treatment decisions.
Materials and Methods
Task forces were independently assembled through the Workforce on Evidence-Based Surgery of the Society of Thoracic Surgeons (STS) and the Thoracic Oncology Network of the American College of Chest Physicians (ACCP) to address high-risk patients with stage I NSCLC, because of commonality of interest, efforts were combined and a multidisciplinary writing committee was assembled. Relevant population, intervention, comparison, and outcome (PICO) questions were formulated and provided to an independent evidence-based investigator in January 2010. In addition, targeted searches were run in the OVID version of MEDLINE in February 2010 and limited to publication since 1995, Figure 1 . Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram of records included in evaluation. The primary reasons for exclusion were data not relevant to the topic, data not specifi c to stage I non-small cell lung cancer, data limited to the treatment of adenocarcinoma in situ, duplicate data, or descriptive data without outcomes. PICO 5 population, intervention, comparison, and outcome.
journal.publications.chestnet.org English language, and human subjects. Abstracts were reviewed by at least two authors and excluded if duplicative, not targeted to stage I NSCLC, or limited to adenocarcinoma in situ. Data were extracted and graded on quality 6 and relevance to subject ( Fig 1, e-Appendix 1 ) . Limited data quality made a consensus statement more appropriate than clinical guidelines.
All data reference the sixth edition of the American Joint Committee on Cancer lung cancer staging system. 7 The reporting of local recurrence was unifi ed by reviewing recurrence definitions from each trial and placing into one of three categories defi ned in Table 1 .
The consensus panel conferred by conference call, e-mail, and semiannually at national meetings. Agree ments were achieved through iterative discussion and debate. Management suggestions were unanimously agreed upon (perfect consensus) prior to approval by the Workforce on Evidence-Based Surgery and Executive Committee of the STS and the Thoracic Oncology Network, the Council of Networks, and the Board of Regents of the ACCP. Suggestions are based on expert opinion and should not be used for performance measurements or competency purposes.
Results
Medical Assessment
Morbidity following lobectomy via thoracotomy is not trivial, with a 30% to 40% incidence of postoperative complications and 1% to 5% operative mortality rate. 1 -3 Although morbidity is high, many complications do not contribute meaningfully to risk/benefi t decisions, such as urinary tract infections, whereas others, including respiratory failure, can signifi cantly impact survival and quality of life. Respiratory failure remains the leading cause of morbidity and mortality after lobectomy. Patients with advanced lung disease have decreased survival defi ned by the severity of their disease. In patients with COPD, FEV 1 , 35% predicts approximately 10% mortality per year (50% 5-year survival). 8 -11 Careful medical assessment is imperative to identify appropriate ther apy in this population.
The majority of research on preoperative evaluation for major lung resection focuses on pulmonary assessment. The quality of evidence is moderate and comes from retrospective analyses of single-institution prospective databases, which are biased by patient selection. Recent reports from very large, prospective clinical databases (containing physiologic information) and administrative databases (generally without physiologic information) increase the quality of evidence but can still be affected by selection bias.
Treatment-related risk is linked to pulmonary function and numerous other factors. Patients with better lung function going into a procedure are more likely to do well afterward. Early studies relied primarily on baseline measurements for assessing risk, which do not account for the volume or relative contribution of affected parenchyma. Postoperative estimated values of lung function have largely supplanted earlier methods of assessing risk. A variety of techniques are used to assess regional function, including segment method, radionuclide scanning, and quantitative CT scanning. 12 -15 The accuracy of postoperative function estimates is infl uenced by the extent and distribution of emphysema, region of resection, patient's fi tness, and perioperative preparation. 16 Current data on prediction of outcomes are based on thoracotomy. Recent publications suggest that morbidity rates may be lower in patients undergoing video-assisted thoracoscopic surgery resection, 10 , 17 and pulmonary function parameters may not accurately predict complications following video-assisted thoracoscopic surgery lobectomy. 8 There is general agreement that the risk of complications is increased in patients with pulmonary hypertension (pHTN) and idiopathic pulmonary fi brosis (IPF). Overall, patients with IPF have substantially shortened life expectancy and increased risk for mortality and pulmonary complications following resection. 18 , 19 The effects of pHTN on interventional outcomes are less well known. It is unclear whether elevated resting mean pulmonary arterial pressure is predictive of morbidity or mortality. 20 Because of the paucity of data regarding IPF and pHTN, suggestions for physiologic evaluation focus on the effects of COPD on outcomes. preoperative values and 10% to 30% decrease below estimated postoperative predicted (ppo) values. 16 , 21 , 22 A minimum of 3 to 6 months are required to return to 80% to 90% of preoperative values. 16 , 21 -24 The decline in FEV 1 6 weeks after lobectomy is smaller in patients with COPD (0%-8%) than without (16%-20%). 16 , 25 Large observational studies indicate that decreasing FEV 1 (% predicted or ppo) is associated with increased risk for pulmonary and cardiovascular complications, ICU readmission, and prolonged hospitalization. 26 , 27 The OR of complications developing is about 0.1 per 10 percentage point decrease in FEV 1 . 27 , 28 However, FEV 1 accounts for only a portion of the risk for morbidity, which is mostly due to other undefi ned factors. A statistical relationship between mortality and spirometry is more diffi cult to demonstrate due to selection bias in large observational databases and low incidence of operative mortality. One study identifi ed decreasing FEV 1 in association with increased risk of mortality after lobectomy. 29 It is impossible to identify an absolute cutoff value that consistently differentiates normal from high risk, or high from prohibitive risk, because of numerous other factors, including tumor location and contribution of effected segments. However, ppo values , 40% are useful in identifying patients at increased risk in whom individual consideration is warranted. 30 , 31 Diffusion Capacity: Postoperative diffusion capacity of lung for carbon monoxide (D lco) decreases 25% to 30% in the immediate postoperative period and returns to 80% to 90% of preoperative values . 2 months after lobectomy. 16 , 23 Decreasing D lco is associated with increased postoperative morbidity and ICU readmission. 26 , 28 , 32 , 33 Similar to FEV 1 , the rela tive risk of complications increases 10% to 20% per each 10-point decrease in D lco . 26 -28 Decreasing D lco is also associated with an increased risk of operative mortality; the relative risk of mortality increasing 20% to 35% per 10-point decrease in D lco . 27 , 28 Identifying an absolute cutoff that reliably differen tiates acceptable from unacceptable risk is inappro priate, but ppo values , 40% are useful in identifying higher risk patients. 30 -32 FEV 1 and D lco have only modest correlation with each other. D lco can be low in the absence of COPD. 27 , 32 D lco is a strong predictor of postoperative outcomes in patients with normal spirometry and useful in assessing risk in patients without COPD. 26 , 28 , 32 Accurate risk assessment necessitates D lco measurement, but it is absent in . 40% of patients in the United States who undergo major lung resection. 26 , 29 Exercise Testing: Peak oxygen consumption with exercise (p o 2 ) decreases after lobectomy and returns to 85% to 100% of preoperative . 2 months after Summary: There are algorithms for defi ning risk for lung resection, 31 , 41 which provide general cutoffs to trigger additional assessments and suggest cutoffs that differentiate high-from prohibitive-risk patients. However, surgical and anesthetic techniques are continually improving, so current guidelines require continual revision. Identifi cation of patients who are at excess risk from lobectomy remains a clinical decision.
Relevant Outcome Measures
The most commonly reported outcomes after NSCLC resection are hospital morbidity and mortality. 1 -3 Other meaningful outcomes include length of hospitalization, discharge disposition, readmission, return to work, neurocognitive function, breathlessness, pain, cost, and quality of life. Expanding measured outcomes beyond short-term morbidity and mortality, to include health-related functional status, quality of life, and patient satisfaction, is essential when evaluating invasive treatments in frail populations. Relative to patients with other cancers, patients with NSCLC have worse performance status regardless of extent of disease. 42 Although physicians focus on morbidity and mortality, patients will tolerate "highburden" therapy if it results in a return to current health. Patients want to avoid permanent functional or cognitive impairment. 43 Health-related functional status reported via the Short Form-36 is worse in patients who have undergone pulmonary resection than in age-and sex-matched control subjects. 44 Postresection health-related functional status is worse than preoperative status in parameters related to physical capability, social functioning, pain, and mental health. 44 , 45 Preoperative dyspnea and decreased D lco negatively affect postoperative quality of life. 44 Increasing extent of resection is consistently linked to worse physical capability, energy, and pain. 45 Very few series of sublobar resection, SBRT, and RFA report on health-related functional status or qual ity of life. van der Voort and colleagues 46 noted no functional decline and improved emotional status following SBRT in patients with medically inoperable NSCLC. Radiofrequency Ablation of Pulmonary Tumors Response Evaluation (RAPTURE), a multiinstitutional RFA study in high-risk patients, reported no deterioration of Short Form-12 (physical and mental components of Short Form-36) or Functional Assessment of Cancer Therapy-Lung scores. 47 Further assessments of functional health status are essential to adequately assess treatment options in high-risk populations.
Sublobar Resection
Early experience with sublobar resection for stage I NSCLC revealed comparable morbidity, reduced mortality, 48 , 49 and preserved pulmonary function compared with lobectomy. 50 , 51 Enthusiasm waned when the Lung Cancer Study Group (LCSG) demonstrated an increase in regional recurrence (17.2% vs 6.4%) following sublobar resection compared with lobectomy. 52 This represents the only prospective, randomized comparison of lobectomy and sublobar resection for NSCLC and established lobectomy as the surgical standard for early-stage NSCLC. A substantial body of literature has emerged over the last decade resurrecting interest in sublobar resection. Single-institution series consistently demonstrate equivalent regional recurrence and survival for anatomic segmentectomy compared with lobectomy for small node-negative tumors ( Table 2 ) . 53 -59 Increasing age is associated with increased risk following lung resection. 60 , 61 A study from the Surveillance, Epidemiology, and End Results (SEER) program found that lobectomy carried no survival benefi t in patients . 75 years old. 62 Kilic and colleagues 63 reported reduced morbidity and mortality for patients with stage I NSCLC . 75 years old who underwent segmentectomy compared with lobectomy, with no difference in regional recurrence (6% vs 4%) or survival (49.8% vs 45.5%).
Tumor size is important in the evaluation of parenchymal-sparing treatments. Several reports document equivalent disease-free survival when comparing lobectomy and segmentectomy for tumors Յ 2 cm. 64 -66 A review of 1,272 patients found no difference in disease-free survival between lobectomy and segmentectomy for tumors Յ 2 cm. 65 A prospective, randomized, multi-institutional study is being conducted by Cancer and Leukemia Group B (CALGB 140503) 67 evaluating sublobar resection for stage I NSCLC Յ 2 cm, with signifi cant implications for high-risk patients.
Sublobar resections can be performed by anatomic segmentectomy or wedge resection. Interestingly, in the LCSG trial, segmentectomy carried a decreased risk of involved lobe recurrence compared with wedge resection, 52 more closely approximating recurrence and survival following lobectomy. The superiority of segmentectomy as compared with wedge has been demonstrated in multiple series 65 , 68 and is supported by a 2008 evidence-based review. 69 A strict defi nition for adequate margins in sublobar resections remains unresolved, but the involved lobe and regional recurrence decrease with margin distance . 1 cm or greater than the maximum tumor diameter. 63 , 68 , 70 Adjuvant Brachytherapy: Intraoperative brachytherapy is used to decrease involved lobe and regional recurrence associated with sublobar resection. Singleinstitution series report regional failures of 2% to 6% ( Table 3 ) . 66 , 71 -73 The American College of Surgeons Oncology Group (ACOSOG) completed accrual on a prospective randomized trial (Z4032) 74 comparing sublobar resection with or without intraoperative brachytherapy for high-risk stage I NSCLC. 75 After 90 days, postoperative pulmonary function was similar in both arms, and mortality for all patients was 2.7%. Lower lobe tumor location was the only factor associated with drop in FEV 1. 76 Recurrence data are maturing.
Summary: For high-risk patients with stage I NSCLC, anatomic segmentectomy or wide wedge resection is suggested as a parenchymal-sparing alternative to lobectomy. Adjuvant intraoperative brachytherapy appears safe and reduces involved lobe recurrence. Prospective, randomized studies (CALGB 140503 and ACOSOG Z4032) 67 , 74 will better delineate the usefulness of sublobar resec tion in NSCLC.
Conventionally Fractionated Radiation Therapy
Comparisons of conventionally fractionated radiation therapy (CFRT) vs observation in patients with early-stage NSCLC and severe COPD indicate that CFRT can be curative and provides modest prolongation of survival. 77 , 78 A review of 18 studies using CFRT alone for NSCLC 79 included 1,562 patients with medically inoperable stage I NSCLC and reported 34% overall survival and 39% cancer-specifi c survival at 3 years. Primary tumor relapse was 40% and was the predominant reason for treatment failure. Modern CFRT techniques and dose intensifi cation have improved outcomes, but 5-year regional control and overall survival remain suboptimal ( Table 4 ) . 80 -82 Stereotactic Body Radiation Therapy SBRT refers to highly precise and accurate delivery of very conformal and dose-intensive radiation to small-volume targets. Synonymous terms include stereotactic ablative body radiotherapy and stereotactic radiosurgery. It represents more aggressive dose intensifi cation than can be safely achieved with CFRT methods. SBRT requires careful dose distribution and accurate delivery to ensure target coverage despite smaller margins.
Most early SBRT trials in patients with medically inoperable stage I NSCLC were dose-fi nding studies ( Table 5 ) . 83 -92 Larger phase 2 studies have replicated outcomes of early retrospective series ( Table 6 ) . 93 , 94 The recent Radiation Therapy Oncology Group trial, (RTOG 0236) 95 was limited to a homogeneous population with stage I NSCLC treated in a uniform fashion with 60 Gy in three fractions. 94 All patients had biopsy confi rmation of NSCLC and staging with CT and PET scanning and were deemed medically inoperable by an experienced thoracic surgeon or pulmonologist. Indicators defi ning inoperability included FEV 1 , 40%; ppo FEV 1 , 30%; D lco , 40%; hypoxemia or hypercapnia; pHTN; diabetes with endorgan damage; or severe cerebral, cardiovascular, peripheral vascular disease, or chronic heart disease. Primary tumor control of 98%, regional control of 87%, and overall survival of 56% at 3 years were achieved and represent the best outcomes for SBRT in a high-risk population. RTOG 0618 96 used the same treatment regimen but was limited to patients deemed high risk but operable by a thoracic surgeon or pulmonologist; accrual is completed and the results are pending.
These studies demonstrate a dose-response relationship favoring more intensive regimens and higher rates of primary tumor progression with larger tumors. Regimens with biologically equivalent dose (BED) . 100 Gy consistently result in . 90% primary tumor control for T1 tumors and overall survival . 50%. These results are superior to those historically observed with CFRT. A recent meta-analysis indicated overall survival improvement with SBRT compared with CFRT. 97 Toxicity: Most trials report no signifi cant change in pulmonary function parameters following SBRT. Treatment-related toxicities tend to increase with dose, although high-grade toxicities are uncommon and treatment-related deaths are rare. Toxicities include injury to lung, chest wall, brachial plexus, skin, and central thoracic structures, and fatigue. Organ volume, prior thoracic radiation, and radiosensitizing chemotherapy increase the risks of toxicity. An Indiana University study reported excessive toxicity for tumors 108 The level of evidence with regard to RFA and local and regional control is low. Many studies include both primary and metastatic lesions, making it difficult to quantify the effect for NSCLC. Eight studies report specifi cally on outcomes after RFA for stage I NSCLC. 100 , 102 -105 , 109 -111 The primary tumor relapse rate ranges from 8% to 43% ( Table 7 ) . 100 , 102 -105 , 107 , 111 Primary tumor recurrence after RFA for tumors , 3 cm is 22% to 25% 112 and . 50% for tumors . 3 cm. 101 , 102 , 111 Primary tumor relapse rates improve to 8% to 12% when CFRT is added. 101 , 110 Cancer-specifi c survival is the most important parameter in high-risk populations but is not always reported. Two-year cancer-specifi c survival after RFA ranges from 57% to 93%. 47 , 103 , 111 Overall 1-, 2-, and 3-year survival rates are 63% to 85%, 55% to 65%, and 15% to 46% ( Table 7 ) . 113 ACOSOG Z4033, 114 the only prospective, multi-institutional trial evaluating uniform RFA treatment in patients with high-risk, stage I within 2 cm of the proximal bronchial tree (46%) compared with peripheral tumors (17%). 98 Higher central toxicity rates are not consistently observed with less intense SBRT regimens, and most protocols account for tumor location.
Summary: For high-risk patients with stage I NSCLC, defi nitive radiation therapy is an appropriate treatment option with curative potential. There is suffi cient nonrandomized evidence to suggest SBRT over CFRT on the basis of superior survival, local control, and improved patient convenience. SBRT requires specialized equipment and technical expertise. The ACOSOG and RTOG (Z0499/1021) 99 are sponsoring a randomized comparison of SBRT and sublobar resection for high-risk patients with stage I NSCLC, which should help defi ne use of these technologies.
Ablative Therapies
RFA is the most studied ablative technology for NSCLC. There are no randomized trials comparing RFA with other local therapies (ie, SBRT or surgery). There is accumulating experience indicating the feasibility of RFA for medically unresectable stage I NSCLC, 47 , 100 -107 but the literature on effi cacy and long-term outcome remains sparse. There are three NSCLC, has completed accrual and survival data are maturing. 115 Toxicity: Several publications demonstrate no significant loss in lung function after pulmonary RFA. 14 , 103 , 116 Morbidity ranges from 15% to 55%. 102 -104 , 109 -111 The most prominent complications are pneumothorax (16%-54%) and pleural effusion (19%), which are grade 2 adverse events ( Table 8 ) . Other complications include alveolar hemorrhage, bronchopleural fi stula, Figure 2 . Suggestions for minimal reporting in clinical trials evaluating treatment strategies for high-risk stage I non-small cell lung cancer. adeno 5 adenocarcinoma; BAC 5 adenocarcinoma in situ; CHF 5 congestive heart failure; CTCAE V4 5 common terminology criteria for adverse events, version 4; CXR 5 chest radiograph; DLCO 5 diffusing capacity of lung for carbon monoxide; EBUS 5 endobronchial ultrasound; ECOG 5 Eastern Cooperative Oncology Group; EUS 5 endoscopic ultrasound; F/U 5 follow up; GGO 5 ground glass opacity; GTV 5 gross tumor volume; LOS 5 length of stay; LVEF 5 left ventricular ejection fraction; NOS 5 not otherwise specifi ed; NYHA 5 New York Heart Association; PAP 5 pulmonary artery pressure; PFT 5 pulmonary function test; pHTN 5 pulmonary hypertension; PTV 5 planning treatment volume; QOL 5 quality of life; RECIST 5 response evaluation criteria in solid tumors; RFA 5 radio frequency ablation; RTOG 5 Radiation Therapy Oncology Group; RVSP 5 right ventricular systolic pressure; SBRT 5 stereotactic body radiotherapy; segment 5 segmentectomy; VATS 5 video-assisted thoracic surgery; wedge 5 wedge resection.
journal.publications.chestnet.org massive hemoptysis, hemothorax, neuropathy, and pneumonia. 103 , 113 Most complications are of low severity and self-limited. Procedure-related mortality is , 1%; however, RFA in pneumonectomy patients was associated with death in two series. 106 , 117 Summary: For high-risk patients with stage I NSCLC, RFA is a safe treatment option that can be used as a single modality for tumors Յ 3 cm. Primary tumor control is better with smaller tumors, approximating 90% for tumors , 2 cm. Toxicity appears to be decreased compared with SBRT and sublobar resection, but reduced primary tumor control limits enthusiasm for RFA to those patients who are not candidates for those treatments or prefer single-session outpatient intervention.
Discussion
The tendency for early metastasis from NSCLC makes treatment with localized therapies challenging. SBRT, RFA, and sublobar resection have been associated with increased risk for involved lobe and regional recurrence compared with lobectomy. Improvements in radiographic staging and detection of earlier and more indolent cancers tip the risk/benefi t balance for high-risk stage I NSCLC toward less radical interventions. Evidence suggests that in well-staged and properly selected patients, sublobar resection and SBRT provide a curative option with decreased risk of toxicity and death.
The biggest hurdle in evaluating therapeutic options for high-risk patients is lack of uniformity in the reporting among trials. The majority of evidence is retrospective or from single-institution evaluations. Some consistency in reporting exists within a given modality but almost none across modalities. A common language and criteria for evaluation are needed going forward. Simply stating a patient is medically unfi t for lobectomy is inadequate; medical disability needs to be qualifi ed and quantifi ed to allow comparisons between trials. Outcomes must include early and late toxicity, relapse location, and quality-of-life assessment. Suggested minimal reporting information is outlined in Figure 2 . Validated reporting criteria exist for each parameter but are rarely completely reported.
Summary
There are now several treatment options available for high-risk patients with stage I NSCLC. A multidisciplinary approach is essential for the management of individual high-risk patients with NSCLC, and a similar approach is required on an organizational level to further defi ne the appropriate use of each modality.
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